GALE Galenica AG

Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors

Galenica AG / Key word(s): Personnel
Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors

23.01.2025 / 07:00 CET/CEST


Press release

Nadine Balkanyi-Nordmann, an experienced legal, compliance and governance expert, will be recommended for election as a member of the Board of Directors at the next Annual General Meeting of the Galenica Group.

At the upcoming Annual General Meeting on 10 April 2025, a new member will be proposed to shareholders for election to the Galenica Board of Directors: Nadine Balkanyi-Nordmann (born in 1972), a recognised leader and expert in various fields of law. This would restore the Board of Directors to seven members.

 

Chairman of the Galenica Board of Directors Markus Neuhaus comments on the nomination: “I am pleased to propose Nadine Balkanyi-Nordmann for election as a new member on behalf of the entire Board of Directors. She is a respected expert in Switzerland in the field of administrative law and risk management and has extensive knowledge of conducting administrative investigations in the public sector, implementing new regulations and developing compliance programmes. In addition, she is a distinguished lawyer and has in-depth knowledge of the healthcare sector.”

 

Leading expert in financial services and healthcare

Nadine Balkanyi-Nordmann is the founder and CEO of Lexperience AG. She has worked for prominent law firms and major financial institutions and has trained at several international institutions. Following her time practising law at Walder Wyss & Partners in Zurich, the Swiss attorney held management positions for various banks such as UBS, GE Capital Bank and BNP Paribas in Asia, America and Switzerland.

 

Nadine Balkanyi-Nordmann studied law at the University of Zurich and was admitted to the Zurich bar. She also holds an LL.M. (Master of Laws) from Hong Kong University. She has extensive knowledge of corporate governance and conducting administrative investigations in the public sector. She is to reinforce the Board of Directors of the Galenica Group with her expertise in integrating ESG criteria when it comes to listed companies and implementing new regulatory requirements.

 

Nadine Balkanyi-Nordmann will not stand for re-election to the Board of Directors of Sanitas in 2025, a position she has held since 2013.

 

Dates for the diary

11 March 2025

Publication of Annual Results of the Galenica Group 2024

10 April 2025

Annual General Meeting of Galenica Ltd.

22 May 2025 Galenica Group sales update

7 August 2025

Publication of Galenica Group half-year results 2025

 

For further information, please contact:

 

Media Relations:
Tel. 7
E-Mail:
 

Welcome to the Galenica network!
Over 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally. 

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at .



End of Media Release


Language: English
Company: Galenica AG
Untermattweg 8
3027 Bern
Switzerland
Phone: 11
E-mail:
Internet:
ISIN: CH0360674466
Listed: SIX Swiss Exchange
EQS News ID: 2072801

 
End of News EQS News Service

2072801  23.01.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2072801&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
23/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galenica AG

Juan Ros-Padilla
  • Juan Ros-Padilla

Galenica : Quality comes at a price

Galenica is a well-managed and resilient company that has an unassailable dominance of the Swiss pharma distribution and related services. Over the years the company has earned a quality compounder reputation (+12% annualised TRS since IPO) which is reflected in its 20% average premium vs the SMI. Going forward we expect the company to keep a robust TRS profile of 8-9% p.a. (ex M&A). We initiate our coverage with a Neutral rating as its current premium (30%) and the limited upside to our target...

Galenica AG: 1 director

A director at Galenica AG sold 3,000 shares at 83.305CHF and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Galenica nomme Nadine Balkanyi-Nordmann au Conseil d’administration

Galenica AG / Mot-clé(s) : Personnel Galenica nomme Nadine Balkanyi-Nordmann au Conseil d’administration 23.01.2025 / 07:00 CET/CEST Communiqué de presse Nadine Balkanyi-Nordmann, experte expérimentée en droit, compliance et gouvernance, sera proposée à l’élection au Conseil d’administration lors de la prochaine Assemblée générale du Groupe Galenica. Lors de la prochaine Assemblée générale du 10 avril 2025, il sera proposé aux actionnaires d’élire un nouveau membre au Conseil d’administration de Galenica: Nadine Balkanyi-Nordmann (1972), personnalité dirigeante reconnue et experte...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch